Navigation Links
Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinson's Disease at International Neuromodulation Society 10th World Congress
Date:5/26/2011

.

"The results presented today at the INS World Congress add to a growing body of clinical evidence demonstrating that our novel gene therapy approach may provide significant clinical benefits to Parkinson's disease patients," During added. "In the treatment arm of the Phase 2 study, improved motor control was seen at one month, continued virtually unchanged throughout the six-month blinded study period and persisted through 12 months of follow-up. This suggests that the treatment effect from NLX-P101 is meaningful and durable over the long-term."

Drs. During and Kaplitt have been at the forefront of gene therapy research since 1989 and the Phase 2 trial was the culmination of nearly 20 years of progress with their work in gene transfer technology using an adeno-associated virus (AAV) vector (a disabled, non-pathogenic virus). They were the first to demonstrate that AAV could be an effective gene therapy agent in the brain, which they reported in their landmark Nature Genetics paper in 1994. Drs. During, Kaplitt and colleagues subsequently published additional research demonstrating the beneficial effects of AAV-GAD gene therapy for PD in the journal Science in 2002.

About the Phase 2 Study

The trial involved 45 subjects with moderate to advanced PD who were not adequately controlled with current therapies. Medical centers that participated in the study included: Henry Ford Health System; Massachusetts General Hospital; Stanford University School of Medicine; The Feinstein Institute for Medical Research of the North Shore-LIJ Health System; The Ohio State University College of Medicine; University of Colorado School of Medicine; University of Rochester School of Medicine; and Wake Forest University School of Medicine.

Study subjects were randomized to receive either NLX-P101 treatment or sham surgery. Subjects in the NLX-P101 treatment arm received infusions of the genetic material directly into bilateral subt
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
2. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
3. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. GeoVax Presents Data at AIDS Vaccine 2008 Conference
6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
9. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
11. AmeriCares Presents Power of Partnership Award to Baxter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... materialise. Yet, scientists are making progress in devising ... such approach relies on quantum dotsa kind of ... field. A new study demonstrates that changing the ... with electrical impulses can help better control them. ... used as quantum information units, which would produce ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Feb. 5 Amicus Therapeutics (Nasdaq: FOLD ) announced ... Crowley as Chairman of the Board in addition to his ... will succeed Donald J. Hayden, Jr. , who will become ... to elect Mr. Crowley as Chairman of the Board reflects our ...
... Science , by researchers at Rothamsted Research (an institute ... Institute, and the Universities of Exeter, Greenwich and York, ... insects to undertake long-distance migrations, and highlights the remarkable ... cold British winters by migrating south in autumn to ...
... 4, 2010 -- Four Oak Ridge National Laboratory researchers ... research grants as part of the Department of Energy,s ... program, funded under the American Recovery and Reinvestment Act ... support exceptional researchers during the crucial early career years, ...
Cached Biology Technology:Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board 2Migrating insects fly in the fast lane 24 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... species of fish, according to a new study ... tested fish anti-predator behaviour. , Three-spined sticklebacks ... when exposed to additional noise, whereas no effects ... author Dr Irene Voellmy of Bristol,s School of ... environments have increased substantially during the last few ...
(Date:7/24/2014)... A sake brewery has its own microbial terroir, meaning ... resemble those found in the product, creating the final ... the journal Applied and Environmental Microbiology . This ... census of a sake brewery. , Many sake ... author David A. Mills of the University of California, ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... diabetes places a huge burden on its victims and poses ... attacks and stroke cases, but also many other deleterious conditions, ... In Germany alone, some seven million people currently suffer from ... to reach 370 million by the year 2030. Type 2 ...
... A discovery by Monash University scientists could see humble ... ,lab-on-chip, devices capable of detecting diseases such as kidney ... researchers have used ordinary cotton thread and sewing needles ... which is the size of a postage stamp. ...
... may look identicalnot to mention drabto the human eye. But ... are essentially colorblind. A new study published online on February ... reveals that the fish can easily tell one species from ... patterns on their faces. Although scientists have long known ...
Cached Biology News:The pig and its pancreas 2The pig and its pancreas 3How long is a piece of thread? Long enough to save a life 2Fish can recognize a face based on UV pattern alone 2
... Kits without ammonium sulfate are compatible with ... as Taq and AmpliThem™™ DNA polymerases. You ... systems in one experiment by adding your ... the PreMixes supplied with the kit. This ...
... MasterAmp™ PCR Optimization Kits without ammonium sulfate ... in PCR, such as Taq and AmpliThem™™ ... performance of PCR systems in one experiment ... PCR primers into the PreMixes supplied with ...
... Optimization Kits with ammonium sulfate are compatible ... such as Tfl, Tth, and Pfu DNA ... of PCR systems in one experiment by ... primers into the PreMixes supplied with the ...
Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
Biology Products: